.jpg "Acorda Therapeutics (NASDAQ: ACOR)")
Today, the CBO of Acorda Therapeutics (NASDAQ: ACOR), Andrew Hindman, sold shares of ACOR for $1.03M.
See today’s analyst top recommended stocks >>
Currently, Acorda Therapeutics has an average volume of 575.1K.
Four different firms, including Cantor Fitzgerald and Goldman Sachs, currently also have a Sell rating on the stock. Based on 4 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $24.75, reflecting a 2.2% upside.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Acorda Therapeutics, Inc. develops and markets therapeutic products for nervous system disorders. The company’s two main products are Ampyra and Zanaflex Capsules.
